Abeona Therapeutics Updates on Zevaskyn Launch Progress
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Mar 09 2026
0mins
Abeona Therapeutics announced an update on the building momentum in the Company's launch of FDA-approved Zevaskyn, a first-of-its-kind, autologous gene therapy for treating wounds in adult and pediatric patients with recessive dystrophic epidermolysis bullosa, RDEB. Following the optimization of a release assay in 2025, Zevaskyn commercial launch activities commenced in the fourth quarter, with the first patient treatment completed in December prior to a mandatory scheduled facility shutdown. Since resuming manufacturing in late January 2026, multiple biopsies have been collected, a patient has completed treatment with Zevaskyn, and there are ongoing manufacturing runs. Additional biopsies are scheduled for the remainder of this quarter.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ABEO?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on ABEO
Wall Street analysts forecast ABEO stock price to rise
4 Analyst Rating
4 Buy
0 Hold
0 Sell
Strong Buy
Current: 5.780
Low
20.00
Averages
25.17
High
28.00
Current: 5.780
Low
20.00
Averages
25.17
High
28.00
About ABEO
Abeona Therapeutics Inc. is a commercial-stage biopharmaceutical company developing cell and gene therapies for serious diseases. The Company's ZEVASKYN (prademagene zamikeracel) is an autologous cell-based gene therapy for the treatment of wounds in adults and pediatric patients with recessive dystrophic epidermolysis bullosa. Its fully integrated cell and gene therapy cGMP manufacturing facility in Cleveland, Ohio serves as the manufacturing site for ZEVASKYN commercial production. Its development portfolio features adeno-associated virus (AAV)-based gene therapies for ophthalmic diseases with high unmet medical need. Its AAV capsids are being evaluated to improve tropism profiles for a variety of devastating diseases. Its pipeline programs include ABO-504 (Stargardt disease), ABO-503 (X-linked retinoschisis), ABO-505 (autosomal dominant optic atrophy), UX111 (Sanfilippo Syndrome Type A (MPS IIIA)), TSHA-102 (Rett Syndrome), and TSHA-118 (Infantile Batten Disease (CLN1 Disease)).
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Abeona Therapeutics to Participate in Upcoming Investor Conferences
- Investor Conference Schedule: Abeona Therapeutics will participate in two significant investor conferences in June 2026, including a fireside chat at the Jefferies Global Healthcare Conference on June 4, which is expected to attract considerable investor interest.
- Live Webcast Availability: The fireside chat will be accessible via a live webcast on the Investors section of Abeona's website, allowing investors to engage with the company and view a replay of the event for a limited time, enhancing investor relations.
- Product Development Progress: Abeona's ZEVASKYN® is the first autologous cell-based gene therapy designed for treating adults and pediatric patients with recessive dystrophic epidermolysis bullosa (RDEB), showcasing the company's innovative capabilities in the biopharmaceutical sector.
- Manufacturing Facility Advantage: Abeona's cGMP manufacturing facility in Cleveland, Ohio supports the commercial production of ZEVASKYN, ensuring product quality and supply chain stability, which further solidifies its market position.
See More
Abeona Therapeutics Q1 Earnings Beat Expectations
- Strong Earnings Report: Abeona Therapeutics reported a Q1 GAAP EPS of -$0.30, beating expectations by $0.05, indicating an improvement in financial performance that boosts market confidence in future profitability.
- Revenue Growth: The company achieved Q1 revenue of $8.72M, exceeding market expectations by $3.78M, reflecting robust product sales and demand that may lay the groundwork for sustained growth in subsequent quarters.
- Cash Reserves Decline: As of March 31, 2026, cash, cash equivalents, and short-term investments totaled $168.3M, down from $191.4M as of December 31, 2025, highlighting the company's capital utilization in operations and investments.
- ZEVASKYN Development Plans: Abeona aims to activate 7 QTCs by the end of 2026 to meet the doubling patient demand, a strategy that will enhance the company's competitive position and market penetration for its products.
See More
Abeona Therapeutics Reports Q1 2026 Financial Highlights
- ZEVASKYN Adoption Growth: In Q1 2026, Abeona Therapeutics treated three patients with ZEVASKYN®, indicating steady demand growth, with six additional patients expected to undergo biopsies in Q2, further enhancing market acceptance.
- QTC Network Expansion: The company's Qualified Treatment Center network has expanded to six locations, adding New York-Presbyterian/Columbia University Medical Center and Children's Hospital of Philadelphia, which enhances patient access to ZEVASKYN and is expected to strengthen the company's competitive position in the market.
- Improved Financial Performance: The company reported net product revenue of $8.7 million in Q1 2026, a 263% increase from $2.4 million in Q4 2025, demonstrating positive momentum in commercialization, although sales costs rose to $2.7 million accordingly.
- R&D Spending Adjustment: R&D expenses for Q1 2026 totaled $9.6 million, slightly down from $9.9 million in Q1 2025, primarily due to the reclassification of certain costs to selling and administrative expenses following FDA approval, reflecting strategic resource allocation adjustments.
See More
Abeona Therapeutics Set to Announce Q1 Earnings on May 13
- Earnings Announcement: Abeona Therapeutics is set to announce its Q1 earnings on May 13 before market open, with consensus EPS estimate at -$0.35 and revenue estimate at $4.94 million, indicating potential financial struggles ahead.
- Earnings Estimate Revisions: Over the past three months, EPS estimates have seen no upward revisions and three downward adjustments, reflecting a declining market confidence in the company's profitability, which may negatively impact investor sentiment.
- Revenue Estimate Adjustments: Similarly, revenue estimates have not seen any upward revisions and have experienced three downward revisions, suggesting a cautious market outlook on Abeona's product sales prospects, potentially affecting future liquidity.
- Market Response Analysis: Despite the pressure from lowered earnings and revenue expectations, Abeona is actively promoting ZEVASKYN, targeting the activation of seven QTCs by the end of 2026, which, if successful, could help improve the company's financial situation.
See More
Abeona Activates Children's Hospital as ZEVASKYN Treatment Center
- Treatment Center Expansion: Abeona Therapeutics has announced the activation of the Children's Hospital of Philadelphia as the sixth Qualified Treatment Center, significantly increasing treatment opportunities for patients with Recessive Dystrophic Epidermolysis Bullosa (RDEB), which is expected to enhance patient quality of life.
- Collaborative Innovation: The partnership with the Children's Hospital will leverage their expertise in pediatric care and gene therapy, facilitating the application of ZEVASKYN and providing more patients with treatment opportunities, thereby strengthening the company's market position in gene therapy.
- Significant Treatment Effects: ZEVASKYN, as the first autologous cell-based gene therapy, has demonstrated clinically meaningful wound healing and pain reduction in trials, which is expected to attract more patients seeking treatment and further drive revenue growth for the company.
- Patient Support Program: Abeona Assist offers personalized support to help patients understand their insurance benefits and financial assistance options, which is anticipated to enhance patient satisfaction and loyalty, thereby increasing the company's competitive edge in the market.
See More
Abeona Grants Equity Awards to New Employees
- Equity Award Program: On April 30, 2026, Abeona Therapeutics granted 112,621 restricted shares to eight new non-executive employees as a significant inducement to employment, highlighting the company's commitment to attracting talent.
- Vesting Conditions: The restricted stock will vest one-third annually on each anniversary of the grant date, ensuring employee retention over three years, which enhances loyalty and stability within the company.
- Company Background: Abeona is a commercial-stage biopharmaceutical firm focused on developing cell and gene therapies for serious diseases, with ZEVASKYN® being the first autologous cell-based gene therapy for a specific skin condition, indicating substantial market potential.
- Future Outlook: The company faces challenges including its ability to successfully commercialize ZEVASKYN and meet production demands, factors that will directly impact its future market performance and investor confidence.
See More
Abeona Therapeutics to Participate in Upcoming Investor Conferences
- Investor Conference Schedule: Abeona Therapeutics will participate in two significant investor conferences in June 2026, including a fireside chat at the Jefferies Global Healthcare Conference on June 4, which is expected to attract considerable investor interest.
- Live Webcast Availability: The fireside chat will be accessible via a live webcast on the Investors section of Abeona's website, allowing investors to engage with the company and view a replay of the event for a limited time, enhancing investor relations.
- Product Development Progress: Abeona's ZEVASKYN® is the first autologous cell-based gene therapy designed for treating adults and pediatric patients with recessive dystrophic epidermolysis bullosa (RDEB), showcasing the company's innovative capabilities in the biopharmaceutical sector.
- Manufacturing Facility Advantage: Abeona's cGMP manufacturing facility in Cleveland, Ohio supports the commercial production of ZEVASKYN, ensuring product quality and supply chain stability, which further solidifies its market position.
See More
Abeona Therapeutics Q1 Earnings Beat Expectations
- Strong Earnings Report: Abeona Therapeutics reported a Q1 GAAP EPS of -$0.30, beating expectations by $0.05, indicating an improvement in financial performance that boosts market confidence in future profitability.
- Revenue Growth: The company achieved Q1 revenue of $8.72M, exceeding market expectations by $3.78M, reflecting robust product sales and demand that may lay the groundwork for sustained growth in subsequent quarters.
- Cash Reserves Decline: As of March 31, 2026, cash, cash equivalents, and short-term investments totaled $168.3M, down from $191.4M as of December 31, 2025, highlighting the company's capital utilization in operations and investments.
- ZEVASKYN Development Plans: Abeona aims to activate 7 QTCs by the end of 2026 to meet the doubling patient demand, a strategy that will enhance the company's competitive position and market penetration for its products.
See More
Abeona Therapeutics Reports Q1 2026 Financial Highlights
- ZEVASKYN Adoption Growth: In Q1 2026, Abeona Therapeutics treated three patients with ZEVASKYN®, indicating steady demand growth, with six additional patients expected to undergo biopsies in Q2, further enhancing market acceptance.
- QTC Network Expansion: The company's Qualified Treatment Center network has expanded to six locations, adding New York-Presbyterian/Columbia University Medical Center and Children's Hospital of Philadelphia, which enhances patient access to ZEVASKYN and is expected to strengthen the company's competitive position in the market.
- Improved Financial Performance: The company reported net product revenue of $8.7 million in Q1 2026, a 263% increase from $2.4 million in Q4 2025, demonstrating positive momentum in commercialization, although sales costs rose to $2.7 million accordingly.
- R&D Spending Adjustment: R&D expenses for Q1 2026 totaled $9.6 million, slightly down from $9.9 million in Q1 2025, primarily due to the reclassification of certain costs to selling and administrative expenses following FDA approval, reflecting strategic resource allocation adjustments.
See More
Abeona Therapeutics Set to Announce Q1 Earnings on May 13
- Earnings Announcement: Abeona Therapeutics is set to announce its Q1 earnings on May 13 before market open, with consensus EPS estimate at -$0.35 and revenue estimate at $4.94 million, indicating potential financial struggles ahead.
- Earnings Estimate Revisions: Over the past three months, EPS estimates have seen no upward revisions and three downward adjustments, reflecting a declining market confidence in the company's profitability, which may negatively impact investor sentiment.
- Revenue Estimate Adjustments: Similarly, revenue estimates have not seen any upward revisions and have experienced three downward revisions, suggesting a cautious market outlook on Abeona's product sales prospects, potentially affecting future liquidity.
- Market Response Analysis: Despite the pressure from lowered earnings and revenue expectations, Abeona is actively promoting ZEVASKYN, targeting the activation of seven QTCs by the end of 2026, which, if successful, could help improve the company's financial situation.
See More
Abeona Activates Children's Hospital as ZEVASKYN Treatment Center
- Treatment Center Expansion: Abeona Therapeutics has announced the activation of the Children's Hospital of Philadelphia as the sixth Qualified Treatment Center, significantly increasing treatment opportunities for patients with Recessive Dystrophic Epidermolysis Bullosa (RDEB), which is expected to enhance patient quality of life.
- Collaborative Innovation: The partnership with the Children's Hospital will leverage their expertise in pediatric care and gene therapy, facilitating the application of ZEVASKYN and providing more patients with treatment opportunities, thereby strengthening the company's market position in gene therapy.
- Significant Treatment Effects: ZEVASKYN, as the first autologous cell-based gene therapy, has demonstrated clinically meaningful wound healing and pain reduction in trials, which is expected to attract more patients seeking treatment and further drive revenue growth for the company.
- Patient Support Program: Abeona Assist offers personalized support to help patients understand their insurance benefits and financial assistance options, which is anticipated to enhance patient satisfaction and loyalty, thereby increasing the company's competitive edge in the market.
See More
Abeona Grants Equity Awards to New Employees
- Equity Award Program: On April 30, 2026, Abeona Therapeutics granted 112,621 restricted shares to eight new non-executive employees as a significant inducement to employment, highlighting the company's commitment to attracting talent.
- Vesting Conditions: The restricted stock will vest one-third annually on each anniversary of the grant date, ensuring employee retention over three years, which enhances loyalty and stability within the company.
- Company Background: Abeona is a commercial-stage biopharmaceutical firm focused on developing cell and gene therapies for serious diseases, with ZEVASKYN® being the first autologous cell-based gene therapy for a specific skin condition, indicating substantial market potential.
- Future Outlook: The company faces challenges including its ability to successfully commercialize ZEVASKYN and meet production demands, factors that will directly impact its future market performance and investor confidence.
See More
